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ZtaPromyelocytic leukemia protein nuclear bodies (PML NBs) have been implicated in host immune response to
viral infection. PML NBs are targeted for degradation during reactivation of herpes viruses, suggesting that
disruption of PML NB function supports this aspect of the viral life cycle. The Epstein–Barr virus (EBV) Latent
Membrane Protein 1 (LMP1) has been shown to suppress EBV reactivation. Our ﬁnding that LMP1 induces
PML NB immunoﬂuorescence intensity led to the hypothesis that LMP1 may modulate PML NBs as a means of
maintaining EBV latency. Increased PML protein andmorphometric changes in PML NBs were observed in EBV
infected alveolar epithelial cells and nasopharyngeal carcinoma cells. Treatment with low dose arsenic
trioxide disrupted PML NBs, induced expression of EBV lytic proteins, and conferred ganciclovir susceptibility.
This study introduces an effective modality to induce susceptibility to ganciclovir in epithelial cells with
implications for the treatment of EBV associated pathologies.l of Medicine, Department of
e Ave, New Orleans, La 70112,
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Epstein–Barr virus (EBV) is a ubiquitous gamma herpes virus with
an estimated 90% of the human population seropositive by adulthood.
Initial infection with EBV is usually subclinical, but may manifest as
infectious mononucleosis. EBV infection eventuates in viral latency
and lifelong persistent infection of the host. Of clinical relevance, EBV
has been implicated in a number of lymphocyte malignancies
including Burkitt's lymphoma, B-cell lymphoproliferative disease,
Hodgkin's disease, T-cell lymphomas, and post transplant lympho-
proliferative disease (Thompson and Kurzrock, 2004). In addition,
EBV infection has been linked with gastric carcinomas and anaplastic
nasopharyngeal carcinoma (Nakamura et al., 1994; Nonoyama et al.,
1973; Oda et al., 1993; Raab-Traub, 2002; Shibata et al., 1991; Takada,
2000; Takano et al., 1994; Tao and Chan, 2007; Vasef et al., 1997;Wolf
et al., 1973). EBV has also been implicated in the progression ofidiopathic pulmonary ﬁbrosis where detectable latent EBV proteins in
lung epithelial tissue portend a poorer prognosis (Tang et al., 2003).
Maintenance of viral latency is essential for host immune evasion
and viral persistence. The EBV encoded Latent Membrane Protein 1
(LMP1) is required for EBVmediated immortalization of B-cells, and is
a bona ﬁde oncogene as demonstrated by its ability to transform
rodent ﬁbroblast (Eliopoulos et al., 1996; Moorthy and Thorley-
Lawson, 1993; Peng and Lundgren, 1992; Wang et al., 1985). LMP1
signaling is constitutive and has been reported to upregulate
interferon stimulated genes creating an antiviral environment within
the cell (Zhang et al., 2004, 2001). Additionally, conditional
expression of LMP1 in EBV infected cells has been shown to inhibit
reactivation of the EBV lytic program (Adler et al., 2002).
Current antiviral therapies targeting EBV positive cells rely on the
activation of nucleoside analogue pro-drugs by a viral-speciﬁc protein
kinase which is expressed only during the lytic phase (Meng et al.,
2010). Given that the virus is latent in the majority of EBV positive
tumors, several strategies have been employed to enhance lytic
reactivation and induce susceptibility to pro-drug antivirals in cell
culture (Daibata et al., 2005; Feng et al., 2004a, 2004b, 2002; Feng and
Kenney, 2006; Hui and Chiang, 2010; Jung et al., 2007; Moore et al.,
2001;Westphal et al., 2000). Reactivation of the EBV lytic cycle begins
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which activate expression of the early proteins responsible for viral
genomic replication. The EBV immediate early transactivator, Zta, has
been shown to be essential and sufﬁcient to reactivate EBV and
initiate viral replication (Speck et al., 1997). Zta is expressed at a very
low level during latency and mechanisms to prevent spontaneous
reactivation have been proposed (Yin et al., 2004). Zta transactivates
its own expression during reactivation and induces transcription of
Rta, Zta responsive EBV early genes, and cellular genes (Flemington
and Speck, 1990). The EBV early protein, DNA polymerase processivity
factor, is encoded by the BMRF1 gene and is essential for lytic
replication. The BMRF1 gene is Zta responsive and is an indicator of
lytic reactivation (Neuhierl and Delecluse, 2006).
The promyelocytic leukemia protein nuclear body (PML NB) is a
proteinaceous substructure that can inﬂuence a variety of nuclear
processes including transcriptional regulation, telomeremaintenance,
and regulation of apoptosis (Block et al., 2006; Boisvert et al., 2000;
Yeager et al., 1999). The PML protein is a known interferon stimulated
gene (Lavau et al., 1995; Stadler et al., 1995), which suggests a role in
modulating the host's innate cellular response to viral infection.
Targeted disruption of the PML NB by herpes viruses has been
observed at initiation of lytic reactivation and is consistent across the
Herpesviridae family. Members of alpha (Herpes Simplex Virus 1
(HSV1)), beta (Human Cytomegalovirus (CMV)) and gamma (EBV)
subfamilies encoded IE proteins (ICP0, IE1, Zta, respectively) have
been shown to interact with and disperse PML NB by distinctive
mechanisms (Adamson and Kenney, 2001; Ahn et al., 1998; Bowling
and Adamson, 2006; Everett and Maul, 1994; Kelly et al., 1995; Maul
and Everett, 1994). Moreover, at lytic initiation, HSV1, CMV and EBV
genomes localize to PML NB as sites for viral replication compart-
ments prior to PML NB disruption (Bell et al., 2000; Ishov and Maul,
1996; Ishov et al., 1997; Maul et al., 1996).
Despite evidence supporting a role for PML NBs at the initiation of
lytic infection, little is known about the role of PML during latent viral
infection. The reported upregulation of interferon responsive genes
and inhibition of EBV lytic reactivation by LMP1, coupled with the
disruption of PML NBs observed at EBV reactivation led us to
hypothesize that LMP1 may inﬂuence PML NBs and that this
modulation in PML NBs may aid in the maintenance of viral latency.
Here we show that ectopic expression of LMP1 increased PML
expression and concomitantly the intensity of PML NB immunoﬂu-
orescence. Additionally, upregulation of PML NBswas observed in EBV
infected lung epithelial cells and nasopharyngeal carcinoma cells
expressing LMP1. Treatment with low dose arsenic trioxide (ATO)
caused disruption of PML NBs and was sufﬁcient to induce expression
of EBV lytic cycle proteins and confer susceptibility to Ganciclovir
(GCV). These data suggest a role for LMP1-mediated upregulation of
PML and PML NBs in facilitating latency in EBV infection. To our
knowledge, this is the ﬁrst report of PML upregulation as amechanism
for maintaining latent viral infection.
Results
LMP1 induced PML protein expression and increased nuclear body
intensity
LMP1 expression in EBV infected cells has been shown to inhibit
lytic reactivation of EBV (Adler et al., 2002). Previous studies have
shown that PML expression is induced by interferon responsive
elements and other studies have shown that LMP1 induces the
expression of interferon responsive genes during EBV infection (Lavau
et al., 1995; Stadler et al., 1995; Zhang et al., 2001). To test the
hypothesis that LMP1 may regulate PML NB in a way that might
support LMP1's anti-reactivation function, A549 cells were retro-
virally transduced with either an empty backbone vector or the LMP1
expression vector, and were evaluated using immunoﬂuorescentmicroscopy. The control cells displayed the expected punctuate PML
NB staining (Fig. S1). However, the difference in PML NB ﬂuorescence
intensity between the LMP1 positive and control cells was such that,
when exposure time was optimized for the LMP1 positive cells, no
signal was seen in the control cells (Fig. 1A). Quantiﬁcation of PML NB
intensity across the population of cells revealed a signiﬁcant increase
in PML NB ﬂuorescence (Fig. 1B). To examine whether the increase in
PML NB ﬂuorescent intensity observedwith LMP1 expressionwas due
to an increase in PML protein expression rather than increased
localization of PML protein to PML NB or PML NB aggregation, PML
protein expression was examined by western blot (Fig. 1C). LMP1
expression resulted in an increase in all nuclear isoforms of the PML
protein.
LMP1 modulation of PML NB was not autocrine/juxtacrine
To investigate whether the LMP1 induced increase in PML NB
intensity occurs through an autocrine/juxtacrinemechanism, A549 cells
were transiently transfected with the LMP1 expression plasmid or
backbone vector and imaged with immunoﬂuorescence microscopy
4 days later (Figs. 2A and S2). LMP1 expressing cells displayed an
increase in PML NB size and intensity when compared to either
neighboring, non-transfected cells or cells transfected with the
backbone plasmid, suggesting that PML upregulation is a direct effect
of LMP1 expression within the cell. To corroborate theses observations,
A549 cells retrovirally transduced with LMP1expression or empty
vector were grown in trans-well co-culture with non-transduced,
parental A549 cells. No upregulation of PMLwas observed in A549 cells
grown in co-culture with LMP1 infected cells (Figs. 2B and C).
LMP1 expression in EBV infected A549 cells resulted in increased PML
and PML NB intensity
To investigate whether LMP1 expressed at physiological levels
affects PML NB, A549 cells were infected with the BX-1 strain of EBV.
Immunoﬂuorescence imaging of EBV infected cells showed an
increase in PML NB intensity when compared to uninfected parental
cells, consistent with the results using LMP1 retrovirally transduced
A549 cells (Fig. 3A).
ATO increased expression of the lytic transactivator, ZTA, and induced
expression of lytic proteins in EBV infected A549 cells
Expression of the EBV immediate early protein Zta has been shown
to be sufﬁcient to re-activate the lytic cycle in EBV infected cell, and has
been shown to disrupt PML NB upon lytic reactivation (Adamson and
Kenney, 2001; Speck et al., 1997). The increase in PMLNB intensity by a
latent viral protein and disruption of PMLNBby IE lytic proteins suggest
a possible role for PML NB in the maintenance of EBV latency. ATO has
been shown to disrupt PMLNBs bydirect interactionwith the consensus
N-terminus RBCC domain of the PML protein (Zhang et al., 2010). To
investigate the ability of ATO to disrupt PML NB in EBV infected A549
cells, cells were treatedwith varying doses of ATO for 24 h and PMLNBs
were imaged (Figs. 3A and S3). Treatment with ATO concentrations as
low as 6.25 nM resulted in reduction of PML NB size, number and
ﬂuorescent intensity, and treatment with 12.5 nM ATO resulted in
complete loss of PML NB immunoﬂuorescence signal. Quantiﬁcation of
PML NB immunoﬂuorescence intensity demonstrated that PML NB
intensity was diminished by exposure to ATO in a dose dependent
manner. Exposure to 12.5 nM ATO resulted in a PML NB immunoﬂu-
orescence signal below that of baseline untreated uninfected cells
(Fig. 3B). To assess whether EBV positivity affected PML protein levels,
cell fractions from two separate EBV infections (A549bEBVN2C and
A549bEBVN3A) and uninfected parental A549 cells were analyzed by
westernblot. LMP1 expressionwas conﬁrmed in themembrane fraction
of both EBV infected cell lines when compared to uninfected parental
Fig. 1. Effects of LMP1 expression on PML protein expression and PML NB staining intensity. A) Representative ﬁelds of A549 cells retrovirally transduced with empty or LMP1
expression vector and imaged using ﬂuorescent microscopy. PML NBs are shown in green; DAPI is shown in blue (original magniﬁcation of 400×). B) Average total
immunoﬂuorescence intensity of PML NBs in 7 random ﬁelds from control and LMP1 cells normalized to DAPI intensity, were analyzed using ImageJ. C) LMP1 increases PML protein
expression. Western blot analysis of PML and LMP1 expression from 5×106 A549 cells retrovirally transduced with LMP1 expressing or control vectors. Β-Actin was used as a loading
control.
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observed in the nuclear fraction. To investigate whether disruption of
PML NB by ATO treatment was sufﬁcient to induce expression of EBV
lytic proteins, A549bEBVBX1N3A cells were exposed to varying doses
of ATO for 72 hours and Zta was imaged using immunoﬂuorescence
(Figs. 3D and S4A). A physical count of the number of Zta positive cells
from parallel experiments utilizing two separate EBV infections of A549
cells revealed an increase in the number of Zta positive cells in an ATO
dose responsive manner in both cell lines (Fig. 3E). To quantify the
increase in Zta expression,mRNA isolated fromA549bEBVBX1N3Acells
treated with varying doses of ATO for 72 hours was analyzed by qRT-
PCR. ATO treatment induced an increase in Zta mRNA at ATO
concentrations equal to or greater than 12.5 nM (Fig. 3F). Measurement
of the transcript encoding the early protein BMRF1 indicated induction
of the EBV lytic mRNA with doses equal to or greater than 12.5 nM
within 72 hours.
ATO induced expression of EBV lytic transcripts in A549 cells and
conferred GCV susceptibility
To further investigate the effects of ATO on Epstein–Barr early gene
induction, A549bEBVBX1N3A cells were treated with 10 nM ATO, in
the presence or absence of GCV, and transcript levels of Zta and
BMRF1 were assessed over 7 days using qRT-PCR (Fig. 4A). Treatment
with 40 μM GCV alone had no effect on ZTA or BMRF1 mRNA
expression. ATO treatment increased Zta mRNA expression as early asday 3, which increased even further over the ensuing 4 days. The
observed increase in ZTA transcription was reduced at day 7 in GCV/
ATO co-treatment samples when compared to ATO treatment alone.
The increased levels of BMRF1 mRNA after ATO treatment lagged
behind Zta expression, and this increase was abrogated by co-
treatment with GCV/ATO (Fig. 4B). To quantify cell survival following
ATO treatment and to assess susceptibility to GCV, A549bEBVBX1N3A
and uninfected parental cells were treated with 10 nM ATO (plus or
minus GCV) for up to 8 days and Zta was imaged using immunoﬂu-
orescence at 2-day intervals (Fig. 4C). Zta expression was ATO
responsive in a time dependent manner and 100% of the cells stained
positively for Zta at day 8. Co-treatment with ATO and GCV also
resulted in 100% of the cells staining positively for Zta as well as a
reduction in the number of remaining cells (Fig. 4D). To assess
whether the observed cell death required EBV infection,
A549bEBVBX1N3A and uninfected parental cells were treated with
GCV, ATO or GCV plus ATO for 4 days. The cells were stained for
annexin V andwith propidium iodide and viability was assessed using
ﬂow cytometry (Figs. 4E and S4B). Treatment with GCV alone, ATO
alone or co-treatment did not affect the viability of uninfected
parental cells. In contrast, EBV positive cells underwent apoptosis
when treated with ATO alone or with co-treatment. The percentage of
viable cells was reduced from 67% to 35% and 31% with ATO and co-
treatment respectively and there was a concurrent increase in the
percentage of annexin V positive cells from 21% to 58% and 62%. While
the difference between the ATO alone and ATO plus GCV is not
Fig. 2. Effects of LMP1 expression on PML NB in LMP1 negative cells. A) LMP1 does not increase PML in a juxtacrine manner. A549 cells were transfected with the empty or LMP1
expression vectors. At 4 days post transfection, the cells were ﬁxed and stained for LMP1 (red) and PML (green). Nuclei are stained with DAPI (blue) (original magniﬁcation of 600×).
B) Uninfected parental A549 cells were co-cultured with A549 cells retrovirally transduced with the LMP1 or the empty vector for 4 days. PML NBs (imaged with extended exposure
times compared to LMP1 positive cells) are stained in green; nuclei are stainedwith DAPI (blue) (original magniﬁcation of 200×). C) Intensity of PML NBs in three random ﬁelds from
co-culture slides were quantiﬁed and normalized to DAPI intensity using ImageJ.
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decrease in the number of surviving cells between these two groups at
the 8 day time point.
EBV infection increased the intensity of PML NBs in NPC cells
EBV infection ishighly correlatedwith thedevelopmentof anaplastic
nasopharyngeal carcinoma (Nonoyama et al., 1973; Raab-Traub, 2002;
Tao and Chan, 2007; Thompson and Kurzrock, 2004; Vasef et al., 1997;
Wolf et al., 1973). To investigate the effect of EBV infection in NPC cells,CNE1 cells were infectedwith the BX-1 strain of EBV and PML-NBswere
imagedbyﬂuorescentmicroscopy. EBV infection increased the intensity
of PMLNBswhen compared tonon-infectedparental cells, similar to the
effect seen with EBV infection of A549 cells (Figs. 5A and S5A). Further,
treatment with 1 nM ATO was sufﬁcient to disrupt PML NBs in EBV
positive CNE1 cells. Quantiﬁcation of PML NB immunoﬂuorescence
intensity demonstrated that PML NB intensity was diminished by
exposure to ATO in a dose dependent manner. Exposure to 1.0 nM ATO
resulted in a PMLNB immunoﬂuorescence signal below that of baseline
untreated uninfected cells (Fig. 5B).
Fig. 3. Effects of ATO on PML NBs and EBV lytic protein expression in infected A549 cells. A) EBV infection increases the intensity of PML NBs in EBV infected A549 cells, while ATO
disrupts this phenomenon. A549bEBVN3A or parental cells were treated with the indicated doses of ATO for 24 h and imaged for PML (green); nuclei are stained with DAPI (blue)
(original magniﬁcation of 600×). B) PML NB immunoﬂuorescence intensity in lower magniﬁcation images (400×) was measured using ImageJ software. To account for variable cell
number per ﬁeld, the PML signal was normalized to DAPI signal and this PML/DAPI ratio was then normalized to uninfected CNE-1signal (***pb0.005 compared to uninfected
control; ###pb0.005 compared to A549bEBV-BX1Ncontrol without ATO). C)Western blot analysis of nuclear (PML) andmembrane (LMP1) fractions from 5×106 two separate EBV
infections (A549bEBVN2 C and A549bEBVN3A) or uninfected parental A549 cells. βActin was used as a loading control. D) ATO increases the number of Zta positive cells in a dose
dependent manner. A549bEBV-BX1N3A cells were treated with the indicated doses of ATO for 3 days and imaged for Zta (red). Nuclei are stained with DAPI (Blue) (original
magniﬁcation of 100×). E) Count of ZTA positive cells from aminimum of 3 random slide ﬁelds (clone A549bEBVN3A shown in panel B or clone A549bEBVN2C, data not shown) are
expressed as a percentage of total cells. F) ATO induces EBV lytic cycle protein expression in a dose dependent manner. A549bEBV-BX1N3A cells were treated with the indicated
doses of ATO for 24 h. Expression of EBV Zta and BMRF1 mRNA were quantiﬁed using qRT-PCR.
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To more speciﬁcally investigate the effects of disruption of PML NB
on ZTA expression, siRNA directed against the PML transcript or a
control siRNA were transfected into CNE1bBX1Ncells. At day 4 posttransfection, PML and Zta expression were analyzed using immuno-
ﬂuorescence (Figs. 5C and S5C). PML NB immunoﬂuorescence
intensity was greatly reduced in the majority of EBV positive CNE-1
cells transfected with PML siRNA (Fig. 5D). Consistent with the effects
observed with disruption of PML NBs in response to ATO treatment,
Fig. 4. Effects of GCV and ATO in EBV infected A549 cells. ATO induced EBV lytic mRNA and protein expression is time dependent. A549bEBV-BX1N3A cells were co-treated with
10 nM ATO and/or 40 μM GCV as indicated for the indicated times. A) EBV Zta and B) BMRF1 mRNA levels were analyzed using qRT-PCR. C) Immunoﬂuorescent detection of ZTA in
ATO (10 nM) and GCV (40 μM) treated A549bEBVBX1N3A and non-infected parental cells at speciﬁed time points. Nuclei were stained with DAPI (original magniﬁcation of 200×).
D) Cell number per wide ﬁeld (100×) on day 8 of treatment as determined by DAPI count of 6 random slide ﬁelds and normalized to untreated cells (Fig. 4C). E) Apoptosis as
determined using annexin V/PI staining. Control and EBV infected A549 cells were treated with ATO (10 nM) or GCV (40 μM) as indicated and stained for annexin V and Propidium
Iodide. Samples were analyzed using ﬂow cytometry. PI—propidium iodide positive/annexin V negative, annexin V—annexin V positive/propidium iodide negative, (−/−)—negative
for both propidium iodide and annexin V, (+/+)—positive for both propidium iodide and annexin V.
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number of cells expressing Zta (Fig. 5E). EBV infected and uninfected
parental CNE1 cells were transfected with siRNA against the PML
transcript or control siRNA cultured in the presence or absence of
40 μM GCV for 7 days and cells were counted in order to investigate
whether disruption of PML NBs using siRNA induced GCV suscepti-
bility. Treatment of PML speciﬁc siRNA transfected cells with GCV
resulted in a reduction of cells to 20.1% (+/−1.5%) of non-treated EBV
positive control cells (Fig. 5F and S5D).ATO treatment induced expression of EBV lytic cycle transcripts in NPC cells
Current antiviral therapies directed toward EBV positive tumors
require expression of EBV lytic proteins in order to confer suscepti-
bility to antivirals (Kenney, 2006). To investigate the ability of ATO to
induce expression of the EBV lytic transcripts in nasopharyngeal
carcinoma cells, CNE1bEBV-BX1Nand non-infected parental cells
were treated with varying doses of ATO for 48 h and Zta and BMRF1
mRNA levels were measured using qRT-PCR (Fig. 6A). Doses of ATO as
Fig. 5. Effects of EBV infection on PML NBs in nasopharyngeal carcinoma cells. A) CNE1bEBV-BX1N infected and parental cells were treated with ATO (1 nM) for 48 h and stained for
PML (green); nuclei are stained with DAPI (blue) (original magniﬁcation of 1000×). B) PML NB immunoﬂuorescence intensity from the above experiment was measured using
ImageJ software. To account for variable cell number per ﬁeld, the PML signal was normalized to DAPI signal and this PML/DAPI ratio was then normalized to uninfected CNE-1signal
(***pb0.005 compared to uninfected control; ###pb0.005 compared to CNE1bEBV-BX1Ncontrol without ATO). C) CNE1bEBV-BX1Ncells were transfected with siRNA speciﬁc to
PML or control siRNA. At 4 days cells were ﬁxed and stained for PML (green) and Zta (red); nuclei were stained with DAPI (blue) (original magniﬁcation of 100×). D) Fluorescence
intensity of PML NB was quantiﬁed in 10 random ﬁelds from Fig. 5C and normalized to DAPI ﬂuorescence signal. E) Fluorescence intensity of ZTA was quantiﬁed in 10 random ﬁelds
from Fig. 5C and normalized to DAPI ﬂuorescence signal. F) CNE1bEBV-BX1Ncells were transfected with siRNA speciﬁc to PML or control siRNA and cultured in the presence or
absence of 40uM GCV. At 7 days, cell nuclei were stained with DAPI and counted, and the cell count was normalized to the untreated cell count (**pb0.01 compared to control siRNA;
***pb0.005 compared to control siRNA; ###pb0.005 compared to no GCV).
92 M.D. Sides et al. / Virology 416 (2011) 86–97
Fig. 6. Effects of GCV and ATO in EBV infected CNE-1 cells. A) ATO dose response. CNEbEBV-BX1Ncells were treated with the indicated doses of ATO for 24 h. EBV Zta and BMRF1
mRNA levels were quantiﬁed using qRT-PCR. B) ATO induced expression of EBV Zta in CNE1 cells. EBV infected and parental CNE1 cells were treated with 1 nMATO and/or 40uMGCV
for 8 days and stained for the immediate early EBV gene Zta (red); nuclei are stainedwith DAPI (blue) (original magniﬁcation of 200×). C) Analysis of cell count from 10 random slide
ﬁelds (panel B) analyzed using the ImageJ nucleus counter and normalized to the uninfected non treated cell count (**pb0.01 compared to uninfected; ***pb0.005 compared to
uninfected; ###pb0.005 compared to no GCV). D & E) CNEbEBV-BX1Ncells were co-treated with 1 nM ATO and/or 40uM GCV as indicated for 4 days. EBV Zta and BMRF1 mRNA
levels were analyzed using qRT-PCR.
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BMRF1, indicating induction of the early stage of EBV lytic transcrip-
tion. CNE1bEBV-BX1Nand non-infected parental cells were then
treated with 1 nM ATOwith or without 40 μMGCV for 3 days and ZTA
positive cells were imaged using immunoﬂuorescence (Fig. 6B). ATO
alone and ATO plus GCV treatment increased the number of cells that
were Zta positive.
ATO treatment in EBV positive CNE1 cells conferred GCV susceptibility
and induced cell death
EBV infected and uninfected parental CNE1 cells were treated with
1 nM ATO and 40 mM GCV or co-treated for 4 days and cells were
counted to investigate whether ATO treatment induced GCV suscep-tibility. Co-treatment with GCV and ATO resulted in a reduction of
cells to 26.0% (+/−5.4%) of non-treated EBV positive control cells
(Fig. 6C). In a parallel experiment, EBV positive CNE1 cells were
treated with GCV, ATO or GCV plus ATO for 4 days and ZTA and BMRF1
mRNA expression were quantiﬁed using qRT-PCR (Figs. 6D and E).
Both Zta and BMRF1 mRNA expression were increased with ATO
treatment when compared to control. With co-treatment, both Zta
and BMRF1 mRNA levels were increased, but were well below that
observed with ATO alone.
Discussion
The ability of EBV to evade the host immune system and antiviral
therapy during the latent phase of the EBV lifecycle contributes to the
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expressed, major histocompatibility I expression is inhibited (Sengupta
et al., 2006), and antigen processing and MHC class-I presentation of
EBNA1 (Levitskaya et al., 1995) is interrupted, suppressing the host
adaptive immune response. Expression of LMP1 has been previously
shown to suppress reactivation of the EBV lytic cycle as well as increase
expression of interferon stimulated genes (Adler et al., 2002; Zhang
et al., 2004). PML, aswell as several PML NB components, are interferon
stimulated genes that are thought to contribute to the innate host
response to viral infection (Bernardi and Pandolﬁ, 2007). In this study,
exogenous expression of LMP1 increased PML protein expression, along
with the intensity of PML NB immunoﬂuorescence. Additionally,
upregulation of PML NBs was observed in EBV infected lung epithelial
cells and nasopharyngeal carcinoma cells expressing LMP1. Measure-
ment of the increase of PMLNB intensity can bedifﬁcult since PML levels
and PML NB number are known to ﬂuctuate through the cell cycle and
under injurious conditions (Ching et al., 2005; Dellaire et al., 2006;
Eskiw et al., 2003). The upregulation of PML in this study, however, was
made apparent by the fact that the PML NB signal was more than an
order of magnitude higher in LMP1 expressing cells.
Disruption of PML NBs plays a critical role in the life cycle of herpes
viruses. HSV1-ICP0, CMV-IE1 and EBV-Zta disrupt PML NB at initiation
of acute infection or lytic reactivation (Adamson and Kenney, 2001;
Ahn et al., 1998; Bell et al., 2000; Bowling and Adamson, 2006; Everett
and Maul, 1994; Kelly et al., 1995; Maul and Everett, 1994; Xu et al.,
2001). The conservation of this mechanism throughout the herpes-
viridae family suggests the importance of PML NB disruption at the
initiation of the lytic replication cycle. The lytic reactivation of herpes
viruseswith either environmental arsenic exposure, as well as, the use
of ATO in the treatment of cancers has been previously reported
(Ardalan et al., 2010; Au and Kwong, 2005; Bartolome et al., 1999;
Boom et al., 1988; Nouri et al., 2006; Tanvetyanon and Nand, 2004;
Uede and Furukawa, 2003), although the reactivation of herpes
viruses was not emphasized in the clinical trials. In order to
investigate the role of PML NBs in viral latency in the context of a
therapeutically viable method for treatment of EBV, PML NBs were
targeted for degradation using ATO. ATO was previously shown to
induce the degradation of PML by selectively binding to zinc ﬁnger
motifs in the consensus RBCC domain and promoting polyubiquitina-
tion (Lallemand-Breitenbach et al., 2008; Weisshaar et al., 2008;
Zhang et al., 2010). ATO may, however, have off target effects
involving other sumoylated proteins and pathways (Miller, 2002;
Miller et al., 2002). Regardless, treatment of cells with ATO at
nanomolar concentrations efﬁciently reduced the presence of PML
NBs in A549 and CNE1 cells, and induced EBV lytic cycle protein
expression in infected A549 and CNE1 cells. Additionally disruption of
PML NBs by PML directed siRNA induced expression of the IE gene Zta
and induced GCV susceptibility in EBV infected nasopharyngeal
carcinoma cells. ATO was more uniform compared PML siRNA in
inducing ZTA expression within the CNE1 cells, which may be
attributable to the less than complete disruption of PML NBs using
an siRNA knockdown strategy, compared with the more robust
dissociation of PML NBs using ATO. A comparison of Figs. 5A and S5C
demonstrate subtle differences in PML NB intensity that supports this
notion. Nevertheless, siRNA was as effective as ATO in promoting cell
loss when used in combination with ganciclovir. We suspect that
enough of the CNE1 cells underwent EBV reactivation with PML siRNA
to induce sufﬁcient ganciclovir activation to eliminate neighboring
cells via a bystander effect.
Overexpression of EBNA1 has been shown to decrease PML at the
protein level and PML NB number per cell through promoting
phosphorylation and the polyubiquitination pathway (Sivachandran
et al., 2010, 2008). This was shown convincingly in overexpression
studies in EBV negative cells and in two experiments utilizing the EBV
positive C666-1 cell line, which has been shown to be LMP1 negative
(Cheung et al., 1999). Though we did not speciﬁcally assessexpression of EBNA1 in these cells, it is highly likely that EBNA 1 is
co-expressed with LMP1. As previous studies have suggested that
LMP1 is expressed in NPC (Edwards et al., 2004; Hao et al., 2004), the
model of newly infected CNE-1bEBV-BX1Ncells utilized in this study
is felt to be an accurate cell culture analogue of NPC. In this study,
LMP1 expression alone or in the context of latent EBV infection
increased the level of PML with a concomitant increase in PML NB
immunoﬂuorescence intensity. Disruption of PML NBs resulted in the
expression of EBV lytic gene products. These data suggest a role for
LMP1-mediated upregulation of PML and PMLNBs in themaintenance
of latency in EBV infection.
Current antiviral therapies targeting EBV positive tumors rely on
phosphorylation of pro-drug nucleoside analogues by the viral lytic
stage speciﬁc protein kinase (Meng et al., 2010). Once phosphorylat-
ed, the nucleoside analogues inhibit viral genomic replication, and are
also incorporated into the host genomic DNA inducing apoptosis
(Freeman et al., 1993). Additionally, the activated pro-drug is
transferred to neighboring cells and induces apoptosis through a
“bystander effect” (Connors, 1995; Freeman et al., 1993). This strategy
is ineffective against the virus in the latent stage and requires
exogenous reactivation of the viral lytic phase (Kenney, 2006). Several
agents have been utilized in conjunction with nucleoside analogues to
confer susceptibility. The chemotherapeutics ﬂuorouracil (5-FU), cis-
platinum, gemcitabine, doxorubicin and methotrexate have been
shown to induce EBV lytic cycle and confer GSV susceptibility in both
lymphoid and epithelial EBV positive malignancies (Feng et al., 2004a,
2004b, 2002). The broad histone deacetylase inhibitors sodium
butyrate, valproic acid, trichostatin A (TSA), suberoylanilide hydro-
xamic acid (SAHA), the DNA methyltransferase inhibitor azacytidine,
and gamma radiation have also been utilized to convey GCV
susceptibility with varying, but suboptimal, results (Feng and Kenney,
2006; Hui and Chiang, 2010; Jung et al., 2007; Moore et al., 2001;
Westphal et al., 2000). Rituximab, a chimeric antibody to CD20, in
conjunction with the glucocorticoid, dexamethasone induced GCV
susceptibility in lymphoma cells, though this strategy is speciﬁc to
B-cell tumors (Daibata et al., 2005). In addition, arginine butyrate
selectively induces EBV TK with minimal lytic reactivation of EBV and
has been used in clinical trials in conjunction with GCV in the
treatment of post transplant lymphoproliferative disorder (Faller
et al., 2001; Mentzer et al., 1998). In this study, ATO-induced
expression of EBV lytic protein was shown to be time and dose
responsive. Expression of EBV immediate early and early lytic proteins
was achieved with nanomolar concentrations of ATO over an 8-day
period. Perhaps the most critical aspect of our results from a
potentially clinical standpoint is that after 8 days of exposure to
ATO, Zta expression was observed in 100% of the cells. In EBV infected
cells, ATO treatment induced apoptosis and conferred susceptibility to
GCV treatment with a decrease in both cell number and BMRF1
expression in the remaining cells. Co-treatment with ATO and GCV
resulted in a homogeneous Zta positive population of cells, a statistical
reduction in the number of cells, and reduced BMRF1 expression
across the cell population when compared to ATO treatment alone.
Taken together, these data evoke the possible efﬁcacy of ATO and GCV
co-treatment as therapy for EBV positive associated disorders.
Importantly, at a concentration sufﬁcient to induce expression of
EBV lytic cycle protein expression proﬁle in EBV positive cells, ATO
had no effect on the viability of parental un-infected cells suggesting
that ATO treatment may be a safe alternative to other methods of EBV
reactivation that have been proposed for conferring susceptibility to
antiviral treatment. In support of this concept, the dosage of ATO
currently approved for treatment of relapsed or refractory acute
promyelocytic leukemia resulted in peak serum arsenic level ~400 nM
(Fox et al., 2008). This level of ATO has also been proposed as a
treatment option for relapsing or refractory multiple myeloma
(Berenson and Yeh, 2006; Rollig and Illmer, 2009; Soignet et al.,
2001). GCV is already approved by the FDA for antiviral treatment of
95M.D. Sides et al. / Virology 416 (2011) 86–97CMV and EBV associated disorders. Our ﬁndings suggest that ATOmay
be a useful agent for inducing viral susceptibility in the host, and
provides a rationale for conducting further research to assess the
effects of combination therapy with ATO and GCV on clearing viral
loads and for treatment of EBV associated malignancies using animal
models.
Materials and methods
Cell culture and transfection
Human lung adenocarcinoma cells (A549; display properties of type
II pneumocytes) were obtained from ATCC. CNE1 cells were obtained
from Samuel H. Speck, (Emory University, Atlanta, Georgia, USA) and
have been previously described (LTVCI, 1978; Sizhong et al., 1983).
Retroviral transduction and generation of EBV positive epithelial cells
have been previously described (Sides et al., 2010). Unless otherwise
noted, the EBV positive A549 cells used were the line designated
A549bEBVBX1N3A. All cells were maintained in Dulbecco's minimal
essentialmedium(Invitrogen, EugeneOR) supplementedwith10% fetal
bovine serum (Gemini Bio-Products, West Sacramento CA ) and
100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen). For
transient transfection, cells were plated in 8-chamber LabTek slides
(Fischer Scientiﬁc, Pittsburgh, PA, USA) at an initial density of 3×104
cells per well and transfected with Lipofectamine with Plus reagent
(Invitrogen) according to the manufacturer's instructions. Lipofecta-
mine RNAiMax (Invitrogen) was used in reverse transfection in siRNA
experiments according tomanufacturer's protocol. Akata BX1 cellswere
generously provided by Lindsay Hutt-Fletcher, (LSU School ofMedicine,
Shreveport, LA, USA) and were maintained in RPMI (Invitrogen)
supplemented with 10% fetal bovine serum (Gemini Bio-Products),
10 units/ml penicillin and 10 μg/ml streptomycin (Invitrogen) and
500 μg/ml G418 (Invitrogen # 10131).
Plasmids and reagents
Arsenic trioxide (ATO) (Sigma Aldrich, St Louis MO, #311383) was
used at a concentration of 10 nM for treatment of A549 derived cell
lines and at 1 nM for treatment of CNE1 derived cell lines unless
otherwise noted. Ganciclovir (GCV) (Sigma Aldrich, #G2536) was
used at a concentration of 40 μM unless otherwise noted. The
pcDNA*Flag*LMP1*wt vector was kindly provided by Nancy Rabb-
Traub (UNC-Lineberger Comprehensive Cancer Institute, Chapel Hill,
NC, USA). The siRNA constructs utilized have been previously
described (Oh et al., 2009) and were purchased from Qiagen
(Valencia, CA).
Western blot
Nuclear and membrane cell lysate fractions were separated using
the Qproteome Cell Compartment Kit (Qiagen, #37502) according to
the manufacturer's directions. Brieﬂy, 5×106 cells were harvested in
extraction buffer, then separated by centrifugation and the cytosolic
fraction (supernatant) was removed. The remaining pellet was
resuspended in extraction buffer, separated by centrifugation and
the membrane fraction (supernatant) was removed. After nuclease
treatment, the pellet was resuspended in 500 μl of extraction buffer,
separated by centrifugation and the nuclear fraction (supernatant)
was removed. Nuclear (PML and membrane (LMP1) fractions were
combinedwith 4X Laemmli Buffer (240 mMTris, 8% SDS, 40% glycerol,
10% 2-mercaptoethanol, 0.02% bromophenol blue) and 30 μg of
protein per well were loaded in a 10 well NuPage Mops 4–12%
gradient minigel (Invitrogen). Proteins were separated by electro-
phoresis at 130 V for 1.5 h then transferred for 1.5 h at 30 V to PDVF
membrane (Invitrogen). Protein transfer was veriﬁed by Ponceau-S
staining. Membranes were blocked in 5% BSA in PBST for 1 h prior toapplication of speciﬁed primary antibody overnight at 4 °C. Rabbit
polyclonal primary antibody to PML (Santa Cruz Biotechnologies,
Santa Cruz, CA, #sc-5621) was used at a dilution of 1:200. Rabbit
polyclonal primary antibody to β-Actin (Cell Signaling, #4967) was
used at a dilution of 1:1000. Mouse monoclonal primary antibody to
LMP1 was (B D Bioscience, Bedford, MA, #559898) used at a dilution
of 1:1000. The ﬂuorophore conjugated secondary antibodies IRDye
680 goat anti-mouse IgG (LiCor Lincoln, NE, #926-32220) or IRDye
800CW goat anti-rabbit IgG (LiCor, #926-32211) were used at a
dilution of 1:15,000. Membranes were imaged using the Odyssey
Infrared Imaging System (LiCor).
Immunoﬂuorescence microscopy
A549 cells were plated on 8-chambered Lab-Tek slides at 3×104
cells per well; chemical treatment began 24 h after plating. At
speciﬁed time points, cells were rinsed twice with PBS and ﬁxed in
4% paraformaldehyde (freshly diluted from 16%, Electron Microscopy
Science, Hatﬁeld, PA) for 10 min at room temperature. The cells were
then rinsed twice with PBS and permeabilized with 0.5% Triton X100
(Sigma) in PBS for 15 min at room temperature. Primary antibodies
were applied at speciﬁed concentrations overnight in a humidiﬁed
chamber at 4 °C. Following 3 rinses in PBS, secondary antibodies were
diluted 1:500 and applied for 1 h at room temperature. The chambers
were removed and Vectashield with DAPI (Vector Laboratories,
Burlingame, CA # H1200) was applied with cover slip mount. The
slides were imaged using a Nikon Eclipse 80i microscope and a
SensiCam QE camera (Cooke Corporation) and IPLab V3.65a software
(Scanalytics).
Exposure conditions were optimized for the brightest ﬁeld of the
speciﬁed conditions and held constant for subsequent exposures. The
primary mouse monoclonal antibody (sc-966), and rabbit polyclonal
antibody (sc5621) to PML (dilution 1:500) were purchased from
SantaCruz. The primary monoclonal mouse antibody to LMP1 was
purchased from BD Bioscience (#559898) and used at a dilution of
1:500. The primary antibody to ZTA (#11-007) was purchased from
Argene (Varilhes, France) and used at a dilution of 1:50. The
secondary antibodies Alexa Fluor 594 goat anti-mouse (Invitrogen
#A11005), AlexaFluor 594 goat anti-rabbit (Invitrogen#A21207) and
AlexaFluor 488 goat anti-mouse (Invitrogen #A11008) were used at a
dilution of 1:500.
Quantitative reverse transcription real-time PCR
For quantitative real time reverse transcriptase PCR (qRT-PCR), cells
were plated in 6-well plates at 3×105 cells per well. Cells were
harvested at 24h post-treatment unless otherwise noted. RNA was
isolated using the Qiagen RNeasy Mini Isolation kit as per the
manufacturer's speciﬁcation. Brieﬂy, cells were harvested in RLT buffer
plus beta-mercaptoethanol. Samples were homogenized for 30 s at
maximum rpms using a Tissuemiser homogenizer (Fisher Scientiﬁc).
RNA concentration was quantiﬁed by UV spectroscopy and 1 μg RNA of
each sample was used in a 20 μl reverse transcription reaction using
iScript reverse transcriptase and buffer (BioRad). Equal volumes of
cDNA per sample were used in a 20 μl SyberGreen (BioRad) real-time
PCR reaction in an iQ thermal-cycle (Biorad). Target gene expression
was normalized against 36B4 expression and control sample using the
ΔΔCT formula and expressed as fold change. Primers were purchased
from Integrated DNA Technologies (Coralville, IA). Primer sequences
and run conditions for 36B4 (Shan et al., 2008), ZTA and BMRF1
(Hilscher et al., 2005) have been previously described.
Cell viability analysis
Cell viability was assessed using the Annexin V-FITC apoptosis
Detection kit purchased from Sigma (#APOAF) according to
96 M.D. Sides et al. / Virology 416 (2011) 86–97manufacturer's directions. Brieﬂy, cells were plated at 3×105 cells per
well in 6-well culture dishes. At 24 h, the culture medium was
changed to DMEM+0.5%FBS and cells were treated as indicated. At
4 days post-treatment, the cells were stained for annexin V and with
propidium iodide and analyzed at the Tulane Center for Gene Therapy
using the Beckman/Coulter FC500 ﬂow cytometer and running CXP
software.
Statistical analysis
Individual comparisons were analyzed by two-tailed unpaired
t tests; multiple comparisons were analyzed by ANOVAwith Modiﬁed
Bonferroni post hoc test. A p-value b0.05 was considered signiﬁcant.
For ﬁgures, (*) denotes pb0.05 compared to control, (**) denotes
pb0.01 compared to control, (***) denotes pb0.001 compared to
control, (#) denotes pb0.05 ATO compared to ATO/GCV co-treatment,
(###) denotes pb0.001 ATO compared to ATO/GCV co-treatment.
Data presented is representative of multiple experiments performed
in triplicate. Data is represented as the mean (+/−) SEM.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.04.005.
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